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PLC (phospholipase C) isoenzymes catalyse the conversion of
PtdIns(4,5)P2 into the Ca2+-mobilizing second messenger, Ins-
(1,4,5)P3, and the protein kinase C-activating second messenger,
diacylglycerol. With the goal of identifying additional mammalian
PLC isoenzymes, we screened the NCBI non-redundant database
using a BLAST algorithm for novel sequences with homology
with the conserved PLC catalytic core. Two unique sequences
corresponding to two unknown PLC isoenzymes were identified,
and one of these, designated PLC-η2, was cloned and charac-
terized. Most of the coding sequence of PLC-η2 was constructed
fromtwoESTs (expressedsequence tags),which included an over-
lapping sequence that was confirmed by multiple ESTs and
mRNAs. 5′-RACE (rapid amplification of cDNA ends) also identi-
fied an upstream exon not deduced from available EST or mRNA
sequences. Sequence analysis of PLC-η2 revealed the canoni-
cal domains of a PLC isoenzyme with an additional long C-ter-
minus that contains a class II PDZ-binding motif. Genomic
analyses indicated that PLC-η2 is encoded by 23 exons. RT-PCR
(reverse transcriptase-PCR) analyses illustrated expression of
PLC-η2 in human retina and kidney, as well as in mouse brain,
eye and lung. RT-PCR with exon-specific primers also revealed
tissue-specific expression of four splice variants in mouse that
represent alternative use of sequences in exons 21, 22 and 23.
PLC-η2-specific antisera recognized one of these splice variants
as an approx. 155 kDa species when expressed in COS-7 cells;
PLC-η2 natively expressed in 1321N1 human astrocytoma cells
also migrated as an approx. 155 kDa species. PLC activity was
observed in vitro and in vivo for three different constructs of
PLC-η2, each containing possible alternatively spliced first exons.
Co-expression of PLC-η2 with Gβ1γ 2 dimers of heterotrimeric
G-proteins resulted in marked stimulation of inositol lipid
hydrolysis. Thus PLC-η2 may in part function downstream of
G-protein-coupled receptors.
Key words: G-protein, phosphatidylinositol 4,5-bisphosphate
[PtdIns(4,5)P2], phospholipase C-η2, phospholipase C-eta2,
Gβγ .
INTRODUCTION
PLC (phospholipase C) catalyses the conversion of PtdIns(4,5)P2
into the Ca2+-mobilizing second messenger, Ins(1,4,5)P3, and
the protein kinase C-activating second messenger, diacylglycerol
[1,2]. Inositol lipids also specifically bind to conserved PH (pleck-
strin homology), FYVE, PX (Phox homology) and other domains
[3,4], and therein play additionally important roles, directly
regulating membrane association and/or activity of a broad range
of proteins. By altering the ratio of membrane phosphoinositides,
PLC isoenzymes potentially affect membrane association and
activity of many signalling proteins. Whereas the original concep-
tion of inositol lipid signalling focused on receptor-promoted
regulation of PLC at the plasma membrane, inositol lipids regulate
protein function at many subcellular locations [5–7], and the
presence of PLC isoenzymes in most cellular compartments sug-
gests diverse activities of these signalling proteins.
Given the broad physiological roles played by phosphoinos-
itides, it is not surprising that a large family of PLC isoenzymes
exist [8]. All five classes of PLC (PLC-β, -γ , -δ, -ζ and -ε) contain
canonical PH, EF (elongation factor)-hand, catalytic TIM (triose
phosphate isomerase) barrel and C2 domains, with the exception
of sperm-specific PLC-ζ [9], which lacks a PH domain. PLC-δ
isoenzymes are broadly distributed, but their mechanism of regul-
ation remains elusive [8]. PLC-γ isoenzymes contain SH2 and
SH3 (Src homology 2 and 3) domains, and are regulated by
tyrosine phosphorylation by tyrosine kinase receptors and non-
receptor tyrosine kinases [8,10–13]. PLC-β isoenzymes are ela-
borated with a helical C-terminus [14], and are activated directly
by Gα subunits of the Gq family of heterotrimeric G-proteins
[15–17]. Gβγ dimers released from heterotrimeric G-proteins of
the Gi family also activate PLC-β2 and PLC-β3 [18–20]. PLC-ε
is a recently identified isoenzyme containing a CDC25 Ras-GEF
(guanine nucleotide exchange factor) domain at its N-terminus
and two tandem RA (Ras-associating) domains at its C-ter-
minus. Rho and Ras family GTPases activate PLC-ε by two dis-
tinct mechanisms [21–25].
We report here the identification of two members of a new
class of PLC enzyme and describe the molecular cloning and
characterization of one of these proteins, PLC-η2. This enzyme
is activated by Gβγ subunits of heterotrimeric G-proteins.
EXPERIMENTAL
Materials
Inositol-free medium was purchased from ICN Biochemicals
(Costa Mesa, CA, U.S.A.). 3H-Labelled phosphoinositide sub-
strates were prepared from [3H]inositol-labelled turkey erythro-
cytes as described previously [15]. The 1 kb DNA ladder was
purchased from Promega (Madison, WI, U.S.A.).
The SuperScriptTM First-Strand Synthesis System for RT-PCR
(reverse transcriptase-PCR) was obtained from Invitrogen
(Carlsbad, CA, U.S.A.). The Marathon-ReadyTM cDNA kit was
obtained from ClonTech BD Biosciences (Mountain View, CA,
U.S.A.), which includes Marathon-Ready human retina cDNA
(0.1 ng/µl in Tricine/EDTA buffer).
Abbreviations used: AS, antisense; DMEM, Dulbecco’s modified Eagle’s medium; EF, elongation factor; EST, expressed sequence tag; ORF, open
reading frame; PH, pleckstrin homology; PLC, phospholipase C; RACE, rapid amplification of cDNA ends; RT-PCR, reverse transcriptase-PCR; S, sense;
SH, Src homology; TIM, triose phosphate isomerase; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone; UTR, untranslated region.
1 To whom correspondence should be addressed (email tkh@med.unc.edu).
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The gene-specific primers and adaptor primers used for cloning
of human PLC-η2 were as follows: CCATCCTAATACGACTCA-
CTATAGGGC (adaptor primer, P1), ACTCACTATAGGGCT-
CGAGCGGC (adaptor primer, P2), GGACATCATCTTGTA-
GAAGGCACAGA (P3), CGTGGAGTCTGGGGAGGATGCCG
(P4) and GCCTCTTCCATCCCTTCTAGGTACA (P5). The
gene-specific primers used for RT-PCR of the C-terminus of
mouse PLC-η2 were as follows: CAAAAGCCAGAAGCCAA-
GTC [21S (sense)], AGGGATTGAGACCTGCGAGT (22S),
CTCGCAGGTCTCAATCCCTA [22AS (antisense)], ATCT-
CAGGAAGGGTCCCAGT (23S), TCTTCCAGAAGTCCCCT-
CAG (23AS), AGGGTATCCCCTCTTGGAGA (21cS) and
TCTCCAAGAGGGGATACCCT (21cAS). A specific PLC-η2
antibody was generated against the peptide sequence KGSKL-
KKAASVEEGDEG within the X–Y linker region of human PLC-
η2 (Quality Controlled Biochemicals, Hopkinton, MA, U.S.A.).
Identification of the novel PLC-η sequences
The basic local alignment search tool (BLAST) was applied to
screen the non-redundant NCBI database (http://www.ncbi.nlm.
nih.gov) for novel sequences with homology with the sequence
in the conserved catalytic core of known PLC isoenzymes. Two
unique sequences were identified and submitted to the BLAT
search engine on the Santa Cruz genome browser (http://www.
genome.ucsc.edu). The position of each of these unique sequences
was identified in the human genomic sequence, and six human
ESTs (expressed sequence tags), which mapped to the same
genomic region as one of these novel genes (designated PLC-
η2), were obtained from the A.T.C.C. (Manassas, CA, U.S.A.)
and sequenced. The protein sequence corresponding to the ORF
(open reading frame) represented by one EST, BU178908,
was submitted to the SMART website (http://www.smart.embl-
heidelberg.de) for protein domain prediction.
5′-RACE (rapid amplification of cDNA ends)-PCR
A gene-specific primer (P3 or P5) and P1 adaptor primer were
used to amplify the 5′-end of human PLC-η2 using human retina
cDNA (Marathon RACE kit; Clontech BD Biosciences) as a
template. Gene-specific primers (P4 and P5) were used to amplify
a 1 kb product as an internal positive control for the presence
of PLC-η2 transcript. PCR products from RACE reactions were
gel-extracted, cloned into pCR2.1-TOPO vector (Invitrogen) and
transformed into TOP10-competent cells (Invitrogen). Plasmids
were isolated from bacterial cultures with QIAprep Spin Miniprep
kit (Qiagen) and sequenced at the University of North Carolina
DNA sequencing facility.
Construction of human PLC-η2 cDNA
A chimaera of EST1 and EST2 was constructed by ligating the two
sequences at an internal BamHI site present in both ESTs. This
chimaeric sequence is referred to as construct 1′-23, and contains
exon 1′ and exons 2–23. A second human PLC-η2 cDNA sequence
was then constructed by joining the 5′-RACE PCR product with
the EST1/EST2 chimaera at the unique BglII restriction site (see
Figure 1). This sequence is referred to as construct 1–23, and
contains exon 1 and exons 2–23. A third construct corresponding
to exon 2–23 with an exogenously added ATG start codon was
also constructed. All three constructs were cloned into pcDNA4,
which incorporates a His6 tag at the C-terminus.
RT-PCR
Individual mouse tissues (brain, eye and lung) were resuspended
in TRIzol® reagent (Invitrogen). Following addition of chloro-
form, the aqueous and organic phases were separated by centri-
fugation at 14000 g at 4 ◦C for 15 min. The aqueous portion
containing RNA was combined with propan-2-ol to precipitate
RNA, and the sample was centrifuged at 14000 g at 4 ◦C for
10 min. The RNA pellet was then washed in 1 ml of 75% ethanol,
dried and resuspended in DEPC (diethyl pyrocarbonate)-treated
distilled H2O. The concentration of total RNA was determined
by measuring its absorbance at 260 nm. Up to 5 µg of total RNA
was used in a reverse transcription reaction with oligo(dT) primer
and 1 µl of 10 mM dNTPs mix, which was heated to 65 ◦C for
5 min and chilled on ice for at least 1 min. A mixture of 10×
reverse transcription buffer, 25 mM MgCl2, 0.1 M dithiothreitol
and RNaseOUT ribonuclease inhibitor (Invitrogen) was added
to the above RNA mix and incubated at 42 ◦C for 2 min. An
aliquot (1 µl) of reverse transcriptase (Invitrogen) was added and
the reaction was allowed to proceed at 42 ◦C for 50 min. Reverse
transcription was terminated by incubation at 70 ◦C for 15 min. An
aliquot (1 µl) of Escherichia coli RNase H was used to degrade
the template RNA and leave first-strand cDNA. Of this cDNA,
2 µl was then used in each PCR reaction for amplification using
the gene-specific primers 21S, 22S, 22AS, 23S, 23AS, 21cS and
21cAS.
In vitro PLC assay
PLC-η2 (1–23, 1′–23 or 2–23) or PLC-β2 was transiently ex-
pressed in COS-7 cells. Cells were harvested 48 h after trans-
fection using hypotonic buffer with protease inhibitors [leupeptin,
aprotinin, TPCK (N-tosyl-L-phenylalanine chloromethyl ketone)
and PMSF]. The soluble fraction was obtained by centrifugation
at 100000 g for 30 min at 4 ◦C. The total protein concentration of
the soluble fraction was determined by Bio-Rad protein assay.
PLC assays included 5 nmol of PtdIns(4)P or PtdIns(4,5)P2
(Avanti Polar Lipids, Alabaster, AL, U.S.A.) and 10000 c.p.m.
[3H]PtdIns(4)P (prepared from [3H]inositol-labelled turkey ery-
throcytes, as described previously [15]) in a final buffer compos-
ition of 10 mM Hepes/NaOH (pH 7.4), 120 mM KCl, 10 mM
NaCl, 2 mM EGTA, 5.8 mM MgSO4, 0.5% (w/v) cholate and
100 µM free calcium in a final volume of 50 µl. Assays were
incubated at 30 ◦C for 10 min and were terminated by adding
200 µl of 10% (w/v) trichloroacetic acid and 100 µl of 10 mg/ml
BSA. [3H]Ins(1,4)P2 was quantified by liquid-scintillation
counting of the soluble fraction after centrifugation of the reaction
mixture.
In vivo PLC assay
COS-7 cells were seeded in 96-well plates at a density of
8000 cells/well and maintained in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10 % (v/v) fetal bovine
serum at 37 ◦C in an atmosphere of 90 % air/10% CO2. PLC-β1,
PLC-β2, PLC-ε, or PLC-η2 (2–23) plasmid DNA was trans-
fected into COS-7 cells in the absence or presence of expression
vectors for Gα subunits, Gβγ subunits or small GTPases using
Fugene 6 (Roche) transfection reagent according to the manu-
facturer’s protocol. The medium was changed to inositol-free
DMEM containing 1 µCi of [3H]inositol/well 24 h after trans-
fection. After an additional 12 h incubation, [3H]inositol phos-
phate accumulation was initiated by addition of LiCl to a final
concentration of 10 mM. The reaction was stopped after 60 min
by aspiration of the medium and the addition of 50 mM ice-cold
formic acid. [3H]Inositol phosphates were quantified as described
previously [26].
Western blots
COS-7 cell lysates co-expressing PLC-η2 and Gβ1γ 2 were col-
lected in 20 mM Hepes/NaOH buffer, pH 7.4, containing protease
inhibitors (TPCK, PMSF, aprotinin and leupeptin). The soluble
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Figure 1 Identification of a new PLC isoenzyme, PLC-η2
(A) EST chimaera construction and predicted canonical domains of PLC-η2. A BLAST search of the non-redundant NCBI DNA database was conducted, and two novel sequences were identified with
homology with sequences in the conserved catalytic core of known PLC isoenzymes. One of these genes was mapped to human chromosome 1p36.32, and two ESTs (BU178908 and BE908459)
encompassed most of the coding sequence of this gene. Because both ESTs contain a sequence error, they were combined at a common BamHI site to yield a chimaeric cDNA of 4189 bp, representing
a 1389-amino-acid protein. The predicted sequence contains the canonical PH domain, four EF hands, an X and Y catalytic TIM barrel, and a C2 domain of a PLC isoenzyme. A PDZ-binding motif,
LLRL, is present at the C-terminus of the chimaeric sequence. (B) Analysis of the first exon of the EST chimaera. Analysis of the genomic sequence revealed that PLC-η2 is composed of at least
23 exons. Inspection of the first exon of the EST chimaera revealed no in-frame stop codon upstream of the first ATG (shown emboldened and underlined), suggesting that extra sequence exists
upstream of the chimaera. aa, amino acids.
fraction was obtained by centrifugation at 100000 g for 30 min
at 4 ◦C. The total protein concentration of the soluble fraction
was determined by Bio-Rad protein assay. Equivalent samples
were loaded, and immunoreactivity of PLC-η2 was detected by
polyclonal anti-His antibody.
Whole cell lysates from 1321N1 human astrocytoma cells
were collected in 20 mM Hepes/NaOH buffer, pH 7.4, containing
protease inhibitors (TPCK, PMSF, aprotinin and leupeptin). The
soluble fraction was obtained by centrifugation at 13000 g for
20 min at 4 ◦C. Equivalent samples of the whole cell lysates and
the soluble fraction were loaded, and immunoreactivity of PLC-
η2 was detected by polyclonal PLC-η2 antibody with or without
the specific peptide used for PLC-η2 antibody generation. COS-
7 cell lysates expressing PLC-η2(2–23) was used as a positive
control.
RESULTS
With the goal of identifying novel PLC isoenzymes, we conducted
BLAST searches against the non-redundant NCBI DNA database
to identify novel sequences with homology with sequences in the
conserved catalytic core of known PLC isoenzymes. Two unique
sequences were identified and submitted to the BLAT search
engine on the Santa Cruz genome browser. The sequences mapped
to the human genome at positions 1p36.32 and 3q25.31. One of
these, PLC-η1 (3q25.31), was recently reported by Hwang et al.
[27], and therefore is not the focus of this manuscript. Our studies
focused on the gene that mapped to 1p36.32, designated PLC-η2.
Although no apparent full-length genes were indicated in the
1p36.32 subregion (bp positions 2435000–2470000), several
predictive algorithms suggested the existence of ORFs. Addition-
ally, many ESTs mapped to this subregion, and six of these ESTs
were obtained and sequenced. Two of these, BU178908 (EST1)
and BE908459 (EST2), contained nearly full-length sequences
of PLC-η2, with two exceptions: first, a deletion of 146 bp
in exon 23 in BU178908 (not observed in other ESTs) resulted in
a frame-shift and consequently introduced an early stop codon;
and secondly, there was a missing exon (exon 16) in BE908459
(present in all other ESTs; Figure 1A). Moreover, five other ESTs
and mRNAs identified from the University of California, Santa
Cruz (UCSC) genome browser also matched the PLC-η2 sequence
from exon 13 to the end of the gene, strongly suggesting that the
two exceptions mentioned above are artifacts. Thus sequences of
BU178908 and BE908459 were combined at a unique BamHI
site to form a cDNA (EST1/EST2 chimaera) encoding a 1389-
amino-acid protein (Figure 1A). The protein sequence of the
EST1/EST2 chimaera was submitted to the SMART website,
which predicted the presence of a PH domain, four EF-hand
domains [the latter two were predicted by a 3D-PSSM algorithm
(three-dimensional position-specific scoring matrix)], a catalytic
TIM (triose phosphate isomerase) barrel and a C2 domain. Thus
the unique sequence of PLC-η2 comprises the canonical domains
of a PLC isoenzyme. PLC-η2 contains a long C-terminal region,
within which no obvious domain is predicted. However, a class II
PDZ-binding motif, LLRL, is present at the C-terminus of PLC-
η2 (Figure 1A) [28,29], which is conserved in the mouse PLC-η2
sequence, as well as in both human and mouse sequences of
PLC-η1.
Further analysis of the genomic sequence revealed that PLC-η2
comprises at least 23 exons, designated here 1′ to 23 (Figure 1B).
Exon 1′ is designated as such for the reason explained below
in Figure 2. A more detailed illustration of the 3′-end of PLC-
η2, including alternatively spliced exon 22, is shown below
in Figure 4. Since most mammalian genes contain a stop codon in
frame with the start methionine in the 5′-UTR (untranslated
region) of the gene sequence, we analysed the first exon of this
EST chimaera further. Absence of a stop codon in frame with
the start methionine (Figure 1B) suggested that additional coding
c© 2005 Biochemical Society
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Figure 2 Identification of the first exon of human PLC-η2
(A) Amplification of a sequence at the 5′-end of PLC-η2. 5′-RACE PCR was used to clone the 5′-end of PLC-η2 using the P1 adaptor primer and the gene-specific primer P3. Gene-specific primers
P4 and P5 were used to yield an approx. 1 kb product as an internal positive control. (B) Sequence of a new exon of PLC-η2. Human retina cDNA was used as a template, and a 1 kb product was
generated that corresponded to a new first exon and exons 2–5. Analysis of the genomic sequence identified a start ATG and two in-frame stop codons residing in the 5′-UTR region. This newly
identified exon was termed exon 1, and the first exon in the chimaera was termed exon 1′ . (C) Genomic organization of the PLC-η2 gene. The horizontal bar represents the genomic sequence 1p36.32
(bp 2 435 000–2 470 000). The vertical bars represent exons of PLC-η2. Exon 1′ (present in the EST BU178908) lies 8900 bp 5′ to exon 1 (identified from 5′-RACE PCR) in the genomic sequence.
(D) Three constructs of PLC-η2 using different exons at the N-terminus. Three PLC-η2 constructs are graphically represented in this Figure. PLC-η2(1–23) represents exon 1 and exons 2–23.
PLC-η2(1′–23) represents exon 1′ and exons 2–23. PLC-η2(2–23) represents exons 2–23. In exon 1 and exon 1′, non-coding sequences are represented by hatched symbols. All three constructs
were cloned into pcDNA4 vector with a C-terminal His6 tag. aa, amino acids.
sequence might exist 5′ to the first exon in the chimaera. Therefore,
5′-RACE PCR was used to clone the 5′ end of PLC-η2. A gene-
specific primer (P3) and a RACE adaptor primer (P1) were used
to amplify the 5′-end of the gene using human retina cDNA as a
template (Figure 2A). PCR resulted in amplification of an approx.
1 kb fragment corresponding to a new exon (designated exon 1)
and exons 2 to 5 (Figure 2B). Further analysis of this newly
identified first exon revealed two upstream stop codons in frame
with a start methionine, suggesting that this ATG is the correct
start site (Figure 2B). A construct corresponding to exon 1 and
exons 2–23 was generated by joining the newly identified 5′-end
with the chimaeric sequence at the common BglII site to form
a 4248 bp cDNA encoding a 1416-amino-acid protein predicted
to be 155 kDa. Analysis of the genomic sequence at 1p36.32
revealed that the first exon from the EST chimaera (designated
exon 1′) lies 8900 bp upstream of the first exon identified by
RACE PCR (Figure 2C). In addition, an identical 5′-sequence,
encompassing exon 1 to exon 5, was cloned from a human kidney
cDNA library (results not shown). Mammalian expression vectors
(in pcDNA4 with a His6 tag at the C-terminus) were generated
for three different constructs (1–23, 1′–23 and 2–23) of PLC-η2.
These are graphically illustrated in Figure 2(D).
The amino acid sequence of human PLC-η2(1–23) was aligned
with its mouse orthologue in Figure 3. This mouse orthologue of
PLC-η2 is 77.7% identical in overall sequence with human PLC-
η2, 92.4% identical in sequence from the PH to the C2 domain,
and 66.4% identical in the C-terminal tail. The first exon (exon 1)
of human PLC-η2 is well conserved in its mouse orthologue.
However, since no stop codons are present upstream of the
equivalent methionine in mouse PLC-η2, the coding sequence of
the first exon in mouse PLC-η2 potentially begins at a methionine
present 75 residues 5′ to the first methionine of human PLC-
η2. Human PLC-η2 is 41.3% identical in overall sequence with
human PLC-η1, 66.9% identical in sequence from the PH to the
C2 domain, and 17.4 % in the C-terminal tail sequence (Figure 3).
Therefore the PLC-η1 and PLC-η2 sequences are well conserved
in their catalytic core, but PLC-η1 apparently contains additional
sequence in the C-terminal region beyond the C2 domain. The
PDZ-binding domain, LLRL, is conserved in both PLC-η1 and
PLC-η2 from fugu (the Japanese puffer fish) to human, suggesting
a potential interaction site for other signalling proteins.
The form of human PLC-η2 identified and characterized in
the present study, and the mouse sequence of PLC-η2 illustrated
in Figure 3, both differ from the mouse sequence recently reported
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Figure 3 Sequence alignment of human and mouse PLC-η2 with human PLC-η1
Both human and mouse protein sequences of PLC-η2 (accession number: human DQ176850, mouse DQ176851) were aligned with those of PLC-η1 (accession number: NM 014996, NM 183191).
Conserved residues are highlighted in black, and similar residues are highlighted in grey. Domains of PLC-η2 are boxed and labelled. Each exon border is marked with a caret ( ).
by Nakahara et al. [30] within the C-terminus. This difference
is due to alternative splicing, and Figure 4(A) illustrates five
predicted splice variants at the C-terminus of the mouse gene. For
example, 21a/23 refers to a splice form containing exon
21a and exon 23, and both human and mouse PLC-η2 sequences
shown in Figure 3 are 21a/23 splice forms. Other potential splice
c© 2005 Biochemical Society
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Figure 4 Diagram of splice variants of mouse PLC-η2 at the C-terminus
(A) Mouse PLC-η2 C-terminal exon–intron structure and predicted splice variants. Three alternative splice forms occur at exon 21 (21a, 21b or 21c). The absence or presence of exon 22 also
represents a splicing event. The sizes of the cDNA sequence of each exon are indicated, and five predicted splice variants and their alternative use of exons are graphically illustrated. In-frame stop
codons are marked using asterisks (*). The solid horizontal grey bars represent individual exons. The hashed horizontal bar represents the intron between exon 22 and exon 23. (B) The amino acid
sequence encoded by each exon (exon 21 to exon 23) is shown.
Table 1 Protein sizes and mouse tissue distribution of five splice variants
aa, amino acids; ?, unknown.
Protein (aa) Molecular mass (kDa)
Splice form Human Mouse Human Mouse Tissue distribution (mouse)
21a/23 1416 1501 154.7 164.3 Eye, lung
21a/22/23 989 1070 110.2 119.2 Eye
21b/23 1583 1669 171.7 181.4 ?
21b/22/23 1156 1238 127.2 136.3 Eye, brain
21c22/23 1211 1252 132.8 137.7 Eye, brain
forms include 21a/22/23, 21b/23, 21b/22/23 and 21c/22/23. Both
exon 22 and exon 21c encode in-frame stop codons, which would
result in smaller proteins. The amino acid sequence encoded by
each exon is listed in Figure 4(B).
Differences between the form of human PLC-η2 identified and
studied here and that reported from mouse by Nakahara et al. [30]
prompted us to examine mouse RNA for the potential existence
of multiple forms, including exon usage that would encode the
sequence illustrated in Figure 3. Primers designed to each C-
terminal exon were applied in RT-PCR analyses of cDNA reverse-
transcribed from total RNA extracted from mouse eye, brain
and lung to distinguish potential splice forms mentioned above.
Table 1 summarizes protein sizes and mouse tissue distribution of
five splice variants.
Only the 21a/23 splice form (no other variants) was observed in
mouse lung (Figure 5). RT-PCR analyses of mouse brain cDNA
revealed the presence of the 21b/22/23 splice form, as determined
with gene-specific primers (i.e. 21S and 23AS; 21S and 22AS).
This 21b/22/23 form was reported by Nakahara et al. [30]. The
21c/22/23 form was not observed in cDNA from mouse brain,
eye or lung using the above primers, but gene-specific primers
directed towards exon 21c (21S and 21cAS; 21cS and 22AS)
revealed the presence of the 21c/22/23 form in mouse eye and
brain. In contrast, four splice forms were observed in mouse eye.
The potential splice form 21b/23 was not observed in our RT-
PCR analysis. In summary, both the mouse sequence reported by
Nakahara et al. [30] and the human PLC-η2 sequence studied here
appear to be legitimately spliced forms of mouse PLC-η2.
Similar to mouse PLC-η2, all of the above splice forms are
possible in humans. Our results indicate that the human PLC-η2
reported here is equivalent to the mouse PLC-η2 21a/23 splice
form. With the goal of identifying expressed forms of native
human PLC-η2, we generated PLC-η2-specific antisera against
a conserved sequence (KGSKLKKAASVEEGDEG) in the
catalytic core of PLC-η2 that is unique to this isoenzyme. These
antisera readily detected a species of approx. 155 kDa in COS-7
cells expressing recombinant human PLC-η2(2–23) (Figure 6).
This immunoreactive species was not observed in empty vector-
transfected COS-7 cells (results not shown). A similar 155 kDa
immunoreactive species was also observed natively expressed
in 1321N1 human astrocytoma cells. A specific peptide used
for PLC-η2 antibody generation blocked the immunoreactivity
associated with the approx. 155 kDa species expressed in COS-7
cells transfected with an expression vector for human PLC-η2,
as well as the immunoreactive species expressed natively in
1321N1 cells. These results with antisera against human PLC-η2
are consistent with expression of both a recombinant and a
natively expressed 155 kDa protein corresponding to the 21a/23
splice form of PLC-η2. Exon-specific primers also indicated
the presence of multiple splice forms in RT-PCR analyses of
cDNA reverse-transcribed from total RNA extracted from human
1321N1 cells and SH-SY5Y human neuroblastoma cells (results
not shown).
The potential activity of PLC-η2 as a functional PLC was tested
in vitro. PLC-η2 (1–23, 1′–23 or 2–23) or PLC-β2 was transiently
expressed in COS-7 cells, and the soluble fraction was isolated
from cell lysates. PLC activity was quantified as described in
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Figure 5 RT-PCR analysis of the carboxyl terminus of PLC-η2 in mouse tissues
The RT-PCR reactions were carried out as described in the Experimental section. The DNA ladder consists of 13 double-stranded, blunt-end fragments with sizes of 250/253, 500, 750, 1000, 1500,
2000, 2500, 3000, 4000, 5000, 6000, 8000 and 10 000 bp. RT-PCR of RNA from mouse eye (lanes 2 and 3) resulted in amplification of the following specific cDNA fragments: 463 bp and 971 bp
using the 21S/23AS primer pair; 179 bp and 687 bp using 21S/22AS; 332 bp using 22S/23AS; 187 bp using 23S/23AS; 945 bp using 21S/21cAS; and 411 bp using 21cS/23AS. RT-PCR of RNA from
mouse brain (lanes 4 and 5) resulted in amplification of the following specific cDNA fragments: 971 bp using 21S/23AS; 687 bp using 21S/22AS; 332 bp using 22S/23AS; 187 bp using 23S/23AS;
945 bp using 21S/21cAS; and 411bp using 21cS/23AS. RT-PCR of RNA from mouse lung (lanes 6 and 7) resulted in amplification of 463 bp using 21S/23AS and 187 bp using 23S/23AS. Each of
the above PCR products was sequenced and confirmed to encode C- terminal sequence of PLC-η2. The positions of molecular-mass markers (MW) is shown in the leftmost lane of either gel.
Figure 6 Expression of native human PLC-η2 in 1321N1 human astrocytoma
cells
Endogenous expression of human PLC-η2 was assessed in whole cell lysates and soluble
fractions prepared from 1321N1 human astrocytoma cells. Immunoblots were developed
using PLC-η2 antibody in the presence or absence of a specific peptide, as described in
the Experimental section. Lysate from COS-7 cells expressing PLC-η2(2–23) was used as a
positive control.
the Experimental section in the presence of [3H]PtdIns(4)P and
0.5% cholate and increasing amounts of total cytosolic protein.
A 5–10-fold increase in phospholipase activity was observed in
homogenates of cells expressing either PLC-η2(1′–23) or PLC-
η2(2–23) (Figure 7A). An approx. 2-fold increase was observed
for the cytosolic fraction obtained from COS-7 cells expressing
PLC-η2(1–23) (Figure 7A). Similar results were obtained using
[3H]PtdIns(4,5)P2 as substrate (results not shown). Western blots
revealed that similar amounts of PLC-η2(1–23), PLC-η2(1′–23),
PLC-η2(2–23) and PLC-β2 were expressed under the conditions
used in these experiments (results not shown). The concentration
of cholate (0.5%) used in these assays is optimal for quantific-
ation of the activity of PLC-β2, and therefore we tested
PLC-η2 phospholipase activity at this cholate concentration.
However, under these assay conditions, PLC-β2 exhibited enzyme
activities that were approximately twice those of PLC-η2(1′–23)
or PLC-η2(2–23). In contrast, higher activities of the PLC-η2
constructs relative to that of PLC-β2 were observed in the absence
of detergent, or with lower concentrations of cholate (Figure 7B).
Taken together, these results illustrate that PLC-η2 functions as
an active PLC against phosphoinositide substrate, and suggest
that the basal activities of the PLC-η2(1′–23) and PLC-η2(2–23)
constructs are greater than that of PLC-η2(1–23).
To determine whether PLC-η2 is activated by G-proteins,
we co-expressed PLC-η2(2–23) with GTPase-deficient mutants
of various Gα subunits and Ras superfamily GTPases, and
measured [3H]inositol phosphate accumulation, as described in
the Experimental section. PLC-β1, PLC-β2 and PLC-ε, which
are known downstream effectors of certain G-proteins [15,19,21],
were also co-expressed with corresponding G-proteins as positive
controls. The construct PLC-η2(2–23) was used in these assays
because it elicits robust lipase activity (Figure 8), and contains
a sequence common to all constructs. Expression of PLC-η2(2–
23) alone increased basal [3H]inositol phosphate accumulation
as much as 2-fold. Under the conditions tested, wild-type Gαq
activated PLC-β1, and the GTPase-deficient mutants of Gα12
(Q226L) and Gα13 (Q229L) activated PLC-ε (Figure 8A). As
expected, expression of RhoA, RhoB or RhoC significantly
increased [3H]inositol phosphate accumulation in COS-7 cells
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Figure 7 PLC-η2 is an active PLC enzyme
Quantification of phospholipase activity at various protein concentrations. COS-7 cells
transiently expressing PLC-β2 or PLC-η2 (1–23, 1′–23 or 2–23) were lysed and the soluble
fraction was obtained to test the lipase activity of each PLC directly in the presence of substrate
[3H]PtdIns(4)P and 0.5 % cholate as described in the Experimental section. The results are
presented as means +− S.E.M. for triplicate determinations. (B) Quantification of phospholipase
activity at various cholate concentrations. Samples were prepared as in (A), and activity was
measured with 200 µg of COS-7 lysate expressing the indicated PLC enzyme and the indicated
concentration of cholate.
expressing PLC-ε, whereas expression of Rac1, Rac2 or Rac3
activated PLC-β2 (Figure 8B). In contrast, no activation of PLC-
η2(2–23) was observed following co-expression with any of
the Gα subunits (wild-type Gαq, Gα11, Gα14 and Gα15/16, and
Gln → Leu mutants of Gαq, Gα11, Gα14, Gα15/16, Gα12, Gα13,
Gαs, Gαolf , Gαi1, Gαi2, Gαi3, GαoA, GαoB, Gαrod and Gαcone)
or Ras-superfamily GTPases (RhoA, RhoB, RhoC, Rac1, Rac2,
Rac3, Cdc42, Cdc42p, TCL, TC10, RhoG, RhoD, Rnd1, Rap1A,
Rap1B, Rap2A and Rap2B) tested (Figure 8, and results not
shown). Thus, although activation of PLC-η2(2–23) may occur
downstream of certain Gα subunits or Ras-family GTPases, no
evidence for such activation was revealed under the conditions
used in our assays.
The capacity of Gβγ to activate PLC-η2 was also examined
in COS-7 cells. As illustrated in Figure 9, co-expression of
increasing amounts of PLC-η2(2–23) with Gβ1γ 2 resulted in
marked elevation of [3H]inositol phosphates compared with cells
expressing PLC-η2(2–23) alone. The extent of activation of PLC-
Figure 8 Screen of potential G-protein activators of PLC-η2
PLC-η2(2–23) was co-expressed with either wild-type or GTPase-deficient mutants of various
Gα subunits (A) or Ras-superfamily GTPases (B), and [3H]inositol phosphate accumulation
was measured as described in the Experimental section. PLC-β1, PLC-β2 or PLC-ε was
co-expressed with certain G-proteins as positive controls. The results are presented as
means +− S.E.M. for triplicate determinations, and are representative of results from two separate
experiments.
η2(2–23) was at least as large as that observed with PLC-ε
under the same conditions. Expression of soluble PLC-η2(2–23),
corresponding to a 155 kDa band on the immunoblot, did not
increase as a consequence of expression of Gβγ (Figure 9, inset),
indicating that the increased activity of PLC-η2(2–23) is a result
of Gβγ -promoted activation, rather than being due to a change in
expression of PLC-η2(2–23).
DISCUSSION
The work described here illustrates the existence of a new isoform
of PLC termed PLC-η2. This isoenzyme contains the conserved
domains found in the catalytic core of all PLC isoenzymes, and
also contains a long C-terminal region. Co-expression of PLC-
η2 with Gβ1γ 2 resulted in a robust increase in inositol lipid
hydrolysis, and therefore this isoenzyme may in part function
downstream of G-protein-coupled receptors.
Most of the coding sequence of PLC-η2 was constructed from
two ESTs, the validity of which was confirmed in the C-terminal
half of the isoenzyme by the existence of multiple mRNAs in the
database exhibiting identical sequences. Our 5′-RACE analyses
c© 2005 Biochemical Society
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Figure 9 Gβγ dimer promotes activation of PLC-η2
The indicated amount of expression vector for PLC-η2(2–23) (left panel) or PLC-ε (right panel)
was co-transfected with 30 ng of expression vector for Gβ1 and 30 ng of expression vector for
Gγ 2 in COS-7 cells. [3H]Inositol phosphate accumulation was quantified as described in the
Experimental section. Data are presented as means +− S.E.M. for triplicate determinations, and
are representative of results from at least five separate experiments. Inset: the level of PLC-η2
in COS-7 cells co-expressed with the indicated amounts of Gβ1 and Gγ 2 DNA was assessed
in immunoblots using anti-His antibody.
using either human retina or kidney cDNA identified an upstream
exon (exon 1) not present in available ESTs or mRNA data.
Indeed, the first exon (exon 1′) present in EST1 (BU178908)
exists far upstream (8900 bp) of the coding sequence we amplified
by 5′-RACE. The sequence amplified from both retinal and
kidney cDNA is encoded by a new exon (exon 1) with two
stop codons in the 5′ UTR in-frame with a start methionine, and
by exon 2 to exon 5. Thus an isoenzyme transcribed from
exon 1 to exon 23 is at least one form of this novel PLC expressed
in human tissues.
Although no functional data were reported, Stewart et al. [31]
recently recognized a sequence for PLC-η2 in the available human
DNA database. The 5′-end of the gene proposed by Stewart and co-
workers potentially represents a splice variant of PLC-η2, since
it differs markedly at the first exon from that confirmed in our
5′-RACE analyses of human cDNA. However, it is unclear from
our analyses of genomic structure how this splice variant would
be formed. Moreover, although the 5′-end of PLC-η2 encoded by
exon 1 (Figure 2) was amplified from two sources of human cDNA
(retina and kidney), we have failed to amplify the 5′ sequence
suggested by Stewart and co-workers applying various primers
constructed on the basis of the unique 5′-end of PLC-η2 reported
by Stewart and co-workers (results not shown).
Alternative splicing also occurs in the C-terminus of PLC-η2.
Indeed, the form of mouse PLC-η2 recently cloned and studied
by Nakahara et al. [30] differs in exon usage in the C-terminal
region from the human PLC-η2 we have cloned and studied.
Although no apparent domains or obvious tertiary structure exists
in this portion of the isoenzyme, our observation of multiple
modes of exon usage and tissue-specific expression of C-terminal
variants of PLC-η2 suggest important functionality in the C-
terminal region of the isoenzyme. For example, mouse lung
exclusively expresses the 21a/23 form, suggesting that the C-
terminal region may be important for the enzyme to function
or interact with other proteins in epithelial tissues. This form
ends with the potential PDZ domain-binding motif LLRL at its
extreme C-terminus, which ostensibly confers specific protein–
protein interactions on lung PLC-η2. Mouse brain expresses both
the 21b/22/23 and 21c/22/23 splice forms. The former variant
has an in-frame ston codon in exon 22, which renders exon 23
an untranslated sequence. The latter form contains an in-frame
stop codon in exon 21c, which renders both exons 22 and
23 untranslated. These two forms may play important roles in
neuronal function. Mouse eye expresses four alternative splice
forms (21a/23, 21a/22/23, 21b/22/23 and 21c/22/23), and it will be
important to establish whether, for example, these exhibit different
functional activities, interact with different regulatory proteins,
are expressed in different development stages, are expressed in
different pools of retinal cells, and/or are localized to different
subcellular compartments.
PLC activity was observed with three different constructs of
PLC-η2, and the activities observed both in vitro and in vivo
are of the order of that quantified with PLC-β2 and other PLC
isoenzymes under similar conditions. Interestingly, the PLC-η2
constructs comprising exons 2–23 or 1′–23 exhibited severalfold-
higher phospholipase activity than the PLC-η2(1–23) construct.
We believe that these data reflect true differences in the activity
of these isoenzyme forms, since similar amounts of soluble and
supposedly fully folded protein were expressed and compared
among the three constructs. Thus one interpretation of these
results is that the presence of exon 1 leads to a decrease in
lipase activity in both in vitro and in vivo measurements of enzyme
activity. No precedent exists for autoinhibition of a PLC en-
zyme, and potential mechanisms whereby the sequence provided
by exon 1 would inhibit lipase activity are not obvious.
Sequence analyses of PLC-η2 revealed all of the canonical
domains of a PLC isoenzyme with an additional long C-terminus
that contains a PDZ domain-binding motif, LLRL. Members
of the PLC-β family containing PDZ domain-binding motifs at
their C-termini have been shown to interact with PDZ domain-
containing proteins, including NHERF (the Na+/H+ exchanger
regulatory factor) [32,33]. NHERF acts as a scaffolding protein
that augments the signal from a G-protein-coupled receptor,
PTH1R (parathyroid hormone 1 receptor), to PLC-β enzymes
in response to parathyroid hormone [34,35]. Whether this
motif in PLC-η2 has unique functionality and whether it serves
as an interaction site for an upstream activator, a downstream
interacting protein, a scaffold protein-binding site, or some other
function needs to be determined.
Activation of PLC-η2(2–23) by Gα subunits of heterotrimeric
G-proteins or by Ras-superfamily GTPases was not observed
under the conditions of our assays. Although predictable activ-
ation of PLC-β and PLC-ε isoenzymes by G-proteins was ob-
served, our results do not unequivocally rule out the possibility
that PLC-η2 lies downstream of signalling pathways promoted by
these or other Gα subunits or Ras GTPases. On the other hand, our
experiments revealed robust activation of PLC-η2 by Gβγ , and
this isoenzyme, like PLC-β2, PLC-β3 [18–20] and PLC-ε [36],
apparently functions downstream of G-protein-coupled receptors
that release Gβγ through activation of heterotrimeric G-proteins,
particularly those of the Gi family. An important current goal is
to purify PLC-η2 to homogeneity and to establish whether Gβγ
or possibly other G-proteins activate this isoenzyme by a direct
mechanism.
Protein sequences in the catalytic core are well conserved
between human PLC-η2 and human PLC-η1 (Figure 3). Hwang
and co-workers [27] have recently reported the identification of
human PLC-η1, in which the exon arrangement is similar to that
of human PLC-η2 in our studies. Based on the sequence alignment
illustrated in Figure 3, PLC-η1 sequence lacks the first exon,
and therefore its coding sequence begins with the PH domain.
c© 2005 Biochemical Society
676 Y. Zhou and others
Sequences of PLC-η1 diverge from those of PLC-η2 in the C-
terminus in that PLC-η1 contains four inserted regions resulting
in an additional 300 amino acids (Figure 3). BLAST analysis
of the C-terminal tails of both PLC-η1 and PLC-η2 yields no
homology with any other proteins in the human database. The
significance of this difference needs further investigation, and
whether the extra sequence in PLC-η1 renders different modes of
regulation will be explored further.
We have not carried out a systematic and rigorous analysis of
the presence of PLC-η2 in human tissues. However, we know from
our PCR analyses that the distribution is relatively broad, since
PLC-η2 RNA is expressed in both human kidney and retina, as
well as in mouse brain, eye and lung. PLC-η2 is natively expressed
as an approx. 155 kDa immunoreactive species in 1321N1 human
astrocytoma cells. This size corresponds to the molecular size of
the PLC-η2(2–23) construct utilized in our characterization
of enzymatic activities of human PLC-η2.
Summary
In conclusion, a second member of the subclass of PLC iso-
enzymes designated as PLC-η has been identified, cloned, and
shown to be activated by Gβγ subunits of heterotrimeric G-pro-
teins. At least 13 different PLC isoenzymes now are known to exist
in mammalian tissues, but our knowledge of the relative roles
played by these signalling proteins remains rudimentary. The ac-
tivities of these isoenzymes clearly are regulated in multiple sub-
cellular compartments by multiple mechanisms. Moreover, we in-
creasingly realize that various membrane phosphoinositides play
important roles in cell signalling in addition to the historically
considered production of Ins(1,4,5)P3 and diacylglycerol from
PtdIns(4,5)P2. Thus it is imperative that we begin to unravel the
functions of PLC-η2 and other PLC isoenzymes at the cellular
level.
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